Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IOT Samsara	$39.19 +2.1%	$42.74	$31.40 ▼ $61.90	$22.27B	1.63	3.99 million shs	4.25 million shs
LYFT Lyft	$16.09 +2.4%	$15.21	$8.93 ▼ $19.07	$6.75B	2.2	16.25 million shs	7.60 million shs
NTLA Intellia Therapeutics	$10.72 -0.1%	$8.77	$5.90 ▼ $28.18	$1.11B	2.21	2.97 million shs	2.81 million shs
OXY Occidental Petroleum	$43.87 -0.1%	$42.54	$34.79 ▼ $64.76	$43.11B	0.84	11.78 million shs	4.58 million shs
PBF PBF Energy	$23.96 +0.5%	$20.61	$13.62 ▼ $45.75	$2.79B	0.84	2.70 million shs	1.21 million shs
REGN Regeneron Pharmaceuticals	$545.00 -0.5%	$549.38	$476.49 ▼ $1,211.20	$59.10B	0.33	905,431 shs	456,413 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IOT Samsara	0.00%	-1.17%	-16.24%	+16.94%	+9.89%
LYFT Lyft	0.00%	+2.32%	+5.41%	+48.39%	+20.13%
NTLA Intellia Therapeutics	0.00%	+12.08%	+39.70%	+61.61%	-53.31%
OXY Occidental Petroleum	0.00%	+2.83%	+4.58%	+7.92%	-29.58%
PBF PBF Energy	0.00%	+9.75%	+33.45%	+60.07%	-47.64%
REGN Regeneron Pharmaceuticals	0.00%	+4.61%	+12.39%	-4.96%	-46.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IOT Samsara	3.1603 of 5 stars	3.3	2.0	0.0	0.0	4.1	4.2	0.0
LYFT Lyft	3.8063 of 5 stars	2.1	2.0	0.0	3.4	1.3	3.3	1.9
NTLA Intellia Therapeutics	4.7165 of 5 stars	4.3	3.0	0.0	4.7	2.1	2.5	0.6
OXY Occidental Petroleum	4.6855 of 5 stars	3.1	4.0	3.3	0.0	2.8	1.7	2.5
PBF PBF Energy	2.3441 of 5 stars	1.8	2.0	1.7	0.0	2.3	3.3	1.3
REGN Regeneron Pharmaceuticals	4.9461 of 5 stars	4.4	5.0	1.7	2.3	2.7	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IOT Samsara	2.50	Moderate Buy	$50.64	29.24% Upside
LYFT Lyft	2.23	Hold	$16.64	3.44% Upside
NTLA Intellia Therapeutics	2.65	Moderate Buy	$33.37	211.42% Upside
OXY Occidental Petroleum	2.14	Hold	$53.38	21.68% Upside
PBF PBF Energy	1.64	Reduce	$23.18	-3.23% Downside
REGN Regeneron Pharmaceuticals	2.80	Moderate Buy	$813.57	49.28% Upside

Current Analyst Ratings Breakdown

Latest NTLA, LYFT, IOT, OXY, PBF, and REGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	REGN Regeneron Pharmaceuticals	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
6/27/2025	LYFT Lyft	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$22.00 ➝ $14.00
6/26/2025	OXY Occidental Petroleum	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$42.00 ➝ $47.00
6/25/2025	IOT Samsara	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$45.00
6/25/2025	IOT Samsara	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$53.00
6/24/2025	LYFT Lyft	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$16.00 ➝ $21.00
6/16/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$7.00
6/16/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/11/2025	PBF PBF Energy	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$18.00 ➝ $21.00
6/9/2025	REGN Regeneron Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$950.00 ➝ $800.00
6/6/2025	IOT Samsara	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$48.00 ➝ $50.00

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IOT Samsara	$1.25B	17.86	N/A	N/A	$1.98 per share	19.79
LYFT Lyft	$5.79B	1.16	$0.26 per share	61.78	$1.83 per share	8.79
NTLA Intellia Therapeutics	$57.88M	19.18	N/A	N/A	$8.56 per share	1.25
OXY Occidental Petroleum	$26.88B	1.61	$11.99 per share	3.66	$27.91 per share	1.57
PBF PBF Energy	$33.12B	0.08	$1.61 per share	14.87	$49.25 per share	0.49
REGN Regeneron Pharmaceuticals	$14.20B	4.14	$45.49 per share	11.98	$268.50 per share	2.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IOT Samsara	-$154.91M	-$0.22	N/A	N/A	N/A	-9.04%	-11.14%	-5.95%	9/4/2025 (Estimated)
LYFT Lyft	$22.78M	$0.15	107.23	32.83	3.17	0.95%	11.28%	1.50%	8/6/2025 (Estimated)
NTLA Intellia Therapeutics	-$519.02M	-$5.23	N/A	N/A	N/A	-1,154.10%	-56.06%	-44.25%	8/14/2025 (Estimated)
OXY Occidental Petroleum	$3.06B	$2.46	17.83	11.39	N/A	11.20%	16.60%	5.18%	8/6/2025 (Estimated)
PBF PBF Energy	-$533.80M	-$9.10	N/A	17.11	N/A	-3.30%	-15.67%	-6.91%	7/31/2025 (Estimated)
REGN Regeneron Pharmaceuticals	$4.41B	$39.28	13.87	14.33	2.00	31.94%	15.27%	11.93%	8/1/2025 (Estimated)

Latest NTLA, LYFT, IOT, OXY, PBF, and REGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/1/2025	Q2 2025	REGN Regeneron Pharmaceuticals	$8.53	N/A	N/A	N/A	$3.30 billion	N/A
7/31/2025	Q2 2025	PBF PBF Energy	-$0.95	N/A	N/A	N/A	$6.65 billion	N/A
6/5/2025	Q1 2026	IOT Samsara	$0.06	$0.11	+$0.05	-$0.04	$351.44 million	$366.88 million
5/8/2025	Q1 2025	LYFT Lyft	$0.20	$0.01	-$0.19	$0.01	$1.47 billion	$1.45 billion
5/8/2025	Q1 2025	NTLA Intellia Therapeutics	-$1.26	-$1.10	+$0.16	-$1.10	$11.39 million	$16.63 million
5/7/2025	Q1 2025	OXY Occidental Petroleum	$0.74	$0.87	+$0.13	$0.77	$6.97 billion	$6.80 billion
5/1/2025	Q1 2025	PBF PBF Energy	-$3.50	-$3.09	+$0.41	-$3.53	$6.27 billion	$7.07 billion
4/29/2025	Q1 2025	REGN Regeneron Pharmaceuticals	$8.83	$8.22	-$0.61	$7.27	$3.40 billion	$3.03 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IOT Samsara	N/A	N/A	N/A	N/A	N/A
LYFT Lyft	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
OXY Occidental Petroleum	$0.96	2.19%	N/A	39.02%	5 Years
PBF PBF Energy	$1.10	4.59%	N/A	N/A	2 Years
REGN Regeneron Pharmaceuticals	$3.52	0.65%	N/A	8.96%	N/A

Latest NTLA, LYFT, IOT, OXY, PBF, and REGN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/1/2025	OXY Occidental Petroleum	quarterly	$0.24	2.4%	6/10/2025	6/10/2025	7/15/2025
5/20/2025	REGN Regeneron Pharmaceuticals	quarterly	$0.88	0.6%	5/20/2025	5/20/2025	6/6/2025
5/2/2025	PBF PBF Energy	quarterly	$0.2750	6.2%	5/15/2025	5/15/2025	5/29/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IOT Samsara	N/A	1.53	1.48
LYFT Lyft	0.66	0.77	0.77
NTLA Intellia Therapeutics	N/A	4.90	4.90
OXY Occidental Petroleum	0.90	1.01	0.79
PBF PBF Energy	0.43	1.29	0.52
REGN Regeneron Pharmaceuticals	0.09	4.93	4.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IOT Samsara	96.02%
LYFT Lyft	83.07%
NTLA Intellia Therapeutics	88.77%
OXY Occidental Petroleum	88.70%
PBF PBF Energy	96.29%
REGN Regeneron Pharmaceuticals	83.31%

Insider Ownership

Company	Insider Ownership
IOT Samsara	46.49%
LYFT Lyft	3.07%
NTLA Intellia Therapeutics	3.10%
OXY Occidental Petroleum	0.31%
PBF PBF Energy	5.30%
REGN Regeneron Pharmaceuticals	7.02%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IOT Samsara	3,500	569.32 million	304.64 million	Not Optionable
LYFT Lyft	2,934	418.01 million	405.18 million	Optionable
NTLA Intellia Therapeutics	600	103.58 million	100.37 million	Optionable
OXY Occidental Petroleum	13,323	984.13 million	981.08 million	Optionable
PBF PBF Energy	3,855	115.65 million	109.52 million	Optionable
REGN Regeneron Pharmaceuticals	15,106	107.96 million	100.39 million	Optionable

NTLA, LYFT, IOT, OXY, PBF, and REGN Headlines

Recent News About These Companies

August 22nd Options Now Available For Regeneron Pharmaceuticals, Inc. (REGN) - Nasdaq

July 5 at 9:38 AM | nasdaq.com

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Braun Stacey Associates Inc.

July 5 at 8:41 AM | marketbeat.com

2 Beaten-Down Stocks to Buy and Hold

July 5 at 7:45 AM | fool.com

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by IFM Investors Pty Ltd

July 5 at 6:28 AM | marketbeat.com

Principal Financial Group Inc. Has $82.21 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

July 5 at 5:30 AM | marketbeat.com

Teacher Retirement System of Texas Trims Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

July 5 at 5:22 AM | marketbeat.com

REGN - Regeneron Pharmaceuticals Inc Valuation - Morningstar

July 4 at 12:06 PM | morningstar.comM

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by GF Fund Management CO. LTD.

July 4 at 8:02 AM | marketbeat.com

Vontobel Holding Ltd. Has $4.66 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

July 4 at 4:44 AM | marketbeat.com

Regeneron Scores Multiple Myeloma Nod for Bispecific, Unlocking $600M Opportunity

July 3 at 4:02 PM | biospace.comB

Regeneron’s Pozelimab Study: A New Hope for Rare Disease Patients

July 3 at 12:20 PM | tipranks.com

FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug

July 3 at 10:20 AM | zacks.com

First Horizon Advisors Inc. Grows Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

July 3 at 7:08 AM | marketbeat.com

Regeneron wins FDA accelerated approval for Lynozyfic in MM

July 3 at 6:46 AM | thepharmaletter.comT

Regeneron Pharmaceuticals (REGN) and Sanofi Announce Approval of Dupixent® By US FDA

July 3 at 6:46 AM | msn.com

Regeneron stock rises after FDA approval for blood cancer therapy

July 2 at 3:44 PM | investing.com

Regeneron Shares Climb Following FDA Approval of Blood Cancer Treatment

July 2 at 3:44 PM | msn.com

Regeneron’s Therapy For Blood Cancer Bags FDA Approval: REGN Stock Jumps

July 2 at 3:44 PM | msn.com

Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment

July 2 at 11:45 AM | wsj.com

US FDA approves Regeneron's blood cancer therapy

July 2 at 11:11 AM | reuters.com

Regeneron Pharmaceuticals Receives FDA Accelerated Approval for Lynozyfic™ in Treating Relapsed or Refractory Multiple Myeloma

July 2 at 11:11 AM | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Blockchain Stocks to Profit in a Decentralized World
By Chris Markoch | June 24, 2025
View 3 Blockchain Stocks to Profit in a Decentralized World
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
By Chris Markoch | June 29, 2025
View 3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
Qualcomm’s Hold Rating Misses Strong Growth Story
By Jeffrey Neal Johnson | July 4, 2025
View Qualcomm’s Hold Rating Misses Strong Growth Story
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
By Nathan Reiff | June 30, 2025
View Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
The Bottom Is in for Powerfleet: An Intelligent Time to Buy
By Thomas Hughes | June 17, 2025
View The Bottom Is in for Powerfleet: An Intelligent Time to Buy

NTLA, LYFT, IOT, OXY, PBF, and REGN Company Descriptions

Samsara NYSE:IOT

$39.18 +0.81 (+2.10%)

Closing price 07/3/2025 03:50 PM Eastern

Extended Trading

$39.18 0.00 (0.00%)

As of 07/3/2025 04:59 PM Eastern

Samsara Inc. provides solutions that connects physical operations data to its connected operations cloud in the United States and internationally. The company's Connected Operations Cloud includes Data Platform, which ingests, aggregates, and enriches data from its IoT devices and has embedded capabilities for AI, workflows and analytics, alerts, API connections, and data security and privacy. Its applications include video-based safety that enables customers to build a safety program and protect their teams with AI-enabled video; vehicle telematics which provides visibility into real-time vehicle location and diagnostics with GPS tracking, routing and dispatch, fuel efficiency management, electric vehicle usage and charge planning, preventative maintenance, and insights to manage fuel and energy costs; and mobile apps and workflows that improves productivity for frontline workers and enables regulatory compliance for workers to see upcoming jobs, capture electronic documents, perform maintenance inspections, maintain compliance logs, and message with back-office administration. The company also provides equipment monitoring which offers visibility and management of unpowered and powered assets, ranging from generators and compressors to heavy construction equipment and trailers to improve operating efficiency, prevent unplanned downtime, and avoid critical safety and compliance issues; and site visibility that provides remote visibility into sites to improve onsite security, safety, and incident response times. It serves transportation, wholesale and retail trade, construction, field services, logistics, utilities and energy, healthcare and education, manufacturing, food and beverage, and other industries, as well as government. Samsara Inc. was incorporated in 2015 and is headquartered in San Francisco, California.

Lyft NASDAQ:LYFT

$16.08 +0.38 (+2.39%)

Closing price 07/3/2025 03:59 PM Eastern

Extended Trading

$16.08 0.00 (0.00%)

As of 07/3/2025 04:59 PM Eastern

Lyft, Inc. operates a peer-to-peer marketplace for on-demand ridesharing in the United States and Canada. It operates multimodal transportation networks that offer access to various transportation options through the Lyft platform and mobile-based applications. The company's platform provides a ridesharing marketplace, which connects drivers with riders; Express Drive, a car rental program for drivers; and a network of shared bikes and scooters in various cities to address the needs of riders for short trips. It also offers centralized tools and enterprise transportation solutions, such as concierge transportation solutions for organizations; Lyft Pink subscription plans; Lyft Pass commuter programs; first-mile and last-mile services; and university safe rides programs. The company was formerly known as Zimride, Inc. and changed its name to Lyft, Inc. in April 2013. Lyft, Inc. was incorporated in 2007 and is headquartered in San Francisco, California.

Intellia Therapeutics NASDAQ:NTLA

$10.72 -0.02 (-0.14%)

Closing price 07/3/2025 03:59 PM Eastern

Extended Trading

$10.66 -0.06 (-0.56%)

As of 07/3/2025 04:57 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Occidental Petroleum NYSE:OXY

$43.87 -0.06 (-0.14%)

Closing price 07/3/2025 03:59 PM Eastern

Extended Trading

$43.81 -0.06 (-0.13%)

As of 07/3/2025 05:00 PM Eastern

Occidental Petroleum Corporation, together with its subsidiaries, engages in the acquisition, exploration, and development of oil and gas properties in the United States, the Middle East, and North Africa. It operates through three segments: Oil and Gas, Chemical, and Midstream and Marketing. The company's Oil and Gas segment explores for, develops, and produces oil and condensate, natural gas liquids (NGLs), and natural gas. Its Chemical segment manufactures and markets basic chemicals, including chlorine, caustic soda, chlorinated organics, potassium chemicals, ethylene dichloride, chlorinated isocyanurates, sodium silicates, and calcium chloride; and vinyls comprising vinyl chloride monomer, polyvinyl chloride, and ethylene. The Midstream and Marketing segment gathers, processes, transports, stores, purchases, and markets oil, condensate, NGLs, natural gas, carbon dioxide, and power. This segment also invests in entities. Occidental Petroleum Corporation was founded in 1920 and is headquartered in Houston, Texas.

PBF Energy NYSE:PBF

$23.96 +0.13 (+0.52%)

Closing price 07/3/2025 03:44 PM Eastern

Extended Trading

$24.08 +0.12 (+0.50%)

As of 07/3/2025 04:20 PM Eastern

PBF Energy Inc., through its subsidiaries, engages in refining and supplying petroleum products. The company operates in two segments, Refining and Logistics. It produces gasoline, ultra-low-sulfur diesel, heating oil, diesel fuel, jet fuel, lubricants, petrochemicals, and asphalt, as well as unbranded transportation fuels, petrochemical feedstocks, blending components, and other petroleum products from crude oil. The company sells its products in Northeast, Midwest, Gulf Coast, and West Coast of the United States, as well as in other regions of the United States, Canada, Mexico, and internationally. It is also involved in the provision of various rail, truck, and marine terminaling services, as well as pipeline transportation and storage services. The company was founded in 2008 and is based in Parsippany, New Jersey.

Regeneron Pharmaceuticals NASDAQ:REGN

$545.00 -2.74 (-0.50%)

Closing price 07/3/2025 03:59 PM Eastern

Extended Trading

$547.81 +2.81 (+0.52%)

As of 07/3/2025 04:57 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NTLA, LYFT, IOT, OXY, PBF, and REGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NTLA, LYFT, IOT, OXY, PBF, and REGN Earnings

Compare Dividends

Latest NTLA, LYFT, IOT, OXY, PBF, and REGN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NTLA, LYFT, IOT, OXY, PBF, and REGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NTLA, LYFT, IOT, OXY, PBF, and REGN Company Descriptions

Samsara NYSE:IOT

Lyft NASDAQ:LYFT

Intellia Therapeutics NASDAQ:NTLA

Occidental Petroleum NYSE:OXY

PBF Energy NYSE:PBF

Regeneron Pharmaceuticals NASDAQ:REGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools